Coherus Oncology Inc (CHRS)

Name: Coherus Oncology Inc Financial Statements
Creator: Quarter Results

Healthcare | Biotechnology

Latest reporting period: 2026-03-31

Latest Quarter

2026-03-31

Revenue

$12.3M

Net Income

-$37.9M

Operating Margin

-293.7%

Free Cash Flow

-$139M

Debt / Assets

76.4%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for Coherus Oncology Inc (CHRS).
Income Statement (Quarterly)	2026-03-31	2025-03-31	2024-12-31	2024-09-30
Revenue	12,310,000	7,599,000	54,144,000	70,774,000
Cost of Revenue	4,695,000	2,653,000	33,858,000	20,741,000
Gross Profit	7,615,000	4,946,000	19,253,000	50,033,000
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	23,104,000	26,025,000	41,297,000	34,744,000
Operating Expenses	43,766,000	50,381,000	62,532,000	56,420,000
Operating Income	-36,151,000	-45,435,000	-42,246,000	-6,387,000
Interest Expense	2,186,000	2,150,000	5,346,000	5,362,000
Income Before Tax	-36,935,000	-47,398,000	-50,696,000	-10,751,000
Income Tax Expense	0	0	0	0
Net Income	-37,939,000	-56,569,000	-50,696,000	-10,751,000
Per Share
EPS	-0.28	-0.49	-0.44	-0.09
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for Coherus Oncology Inc (CHRS).
Income Statement (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue	42,172,000	266,960,000	257,244,000	211,042,000	326,551,000
Cost of Revenue	13,814,000	117,553,000	162,783,000	70,083,000	57,591,000
Gross Profit	28,358,000	149,407,000	94,461,000	140,959,000	268,960,000
Operating Expenses
R&D Expenses	0	0	0	0	0
SG&A Expenses	100,604,000	150,438,000	185,615,000	198,481,000	169,713,000
Operating Expenses	209,492,000	261,074,000	301,451,000	397,839,000	532,818,000
Operating Income	-181,134,000	-111,667,000	-203,199,000	-256,880,000	-263,858,000
Interest Expense	9,001,000	27,158,000	40,542,000	32,474,000	22,959,000
Income Before Tax	-183,124,000	28,507,000	-238,272,000	-291,754,000	-287,100,000
Income Tax Expense	0	0	-380,000	34,874,000	0
Net Income	-170,291,000	28,507,000	-237,892,000	-326,628,000	-287,100,000
Per Share
EPS	-1.45	0.25	-2.53	-4.21	-3.63
EPS Diluted	0.00	0.00	0.00	0.00	0.00

Balance sheet quarterly history for Coherus Oncology Inc (CHRS).
Balance Sheet (Quarterly)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Cash and Cash Equivalents	88,879,000	125,987,000	102,891,000	63,547,000
Short Term Investments	83,246,000	0	14,857,000	128,134,000
Net Receivables	18,418,000	122,334,000	260,522,000	109,964,000
Inventory	3,172,000	70,094,000	62,605,000	115,051,000
Total Current Assets	193,112,000	341,583,000	475,631,000	416,696,000
Property Plant Equipment	0	2,837,000	11,031,000	8,754,000
Goodwill and Intangibles	46,239,000	53,646,000	71,673,000	5,931,000
Total Assets	258,343,000	448,533,000	629,604,000	480,847,000
Liabilities
Account Payables	9,915,000	28,456,000	35,219,000	11,526,000
Short Term Debt	1,828,000	4,530,000	2,145,000	4,318,000
Total Current Liabilities	141,876,000	282,981,000	331,771,000	54,461,000
Long Term Debt	38,508,000	268,213,000	478,697,000	471,058,000
Total Liabilities	197,329,000	580,523,000	823,029,000	618,265,000
Shareholders Equity
Retained Earnings	-1,382,969,000	-1,550,993,000	-1,579,500,000	-1,341,608,000
Total Shareholders Equity	61,014,000	-131,990,000	-193,425,000	-137,418,000

Balance sheet annual history for Coherus Oncology Inc (CHRS).
Balance Sheet (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Assets
Cash and Cash Equivalents	88,879,000	125,987,000	102,891,000	63,547,000	417,195,000
Short Term Investments	83,246,000	0	14,857,000	128,134,000	0
Net Receivables	18,418,000	122,334,000	260,522,000	109,964,000	123,022,000
Inventory	3,172,000	70,094,000	62,605,000	115,051,000	37,642,000
Total Current Assets	193,112,000	341,583,000	475,631,000	416,696,000	602,323,000
Property Plant Equipment	0	2,837,000	11,031,000	8,754,000	7,813,000
Goodwill and Intangibles	46,239,000	53,646,000	71,673,000	5,931,000	3,563,000
Total Assets	258,343,000	448,533,000	629,604,000	480,847,000	679,334,000
Liabilities
Account Payables	9,915,000	28,456,000	35,219,000	11,526,000	16,159,000
Short Term Debt	1,828,000	4,530,000	2,145,000	4,318,000	3,492,000
Total Current Liabilities	141,876,000	282,981,000	331,771,000	54,461,000	165,327,000
Long Term Debt	38,508,000	268,213,000	478,697,000	471,058,000	415,531,000
Total Liabilities	197,329,000	580,523,000	823,029,000	618,265,000	581,608,000
Shareholders Equity
Retained Earnings	-1,382,969,000	-1,550,993,000	-1,579,500,000	-1,341,608,000	-1,049,854,000
Total Shareholders Equity	61,014,000	-131,990,000	-193,425,000	-137,418,000	97,726,000

Cash flow quarterly history for Coherus Oncology Inc (CHRS).
Cash Flow Statement (Quarterly)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Operating Activities
Net Income	168,024,000	28,507,000	-237,892,000	-291,754,000
Depreciation & Amortization	0	5,276,000	3,791,000	3,699,000
Stock Based Compensation	0	27,802,000	43,110,000	50,737,000
Change in Working Capital	-5,842,000	55,894,000	-36,826,000	-79,257,000
Operating Cash Flow	-138,513,000	-20,440,000	-174,884,000	-241,124,000
Investing Activities
Capital Expenditure	0	0	-286,000	-2,039,000
Investments	0	0	-286,000	-2,039,000
Investing Cash Flow	375,087,000	230,321,000	144,640,000	-166,850,000
Financing Activities
Debt Repayment	-233,185,000	-223,408,000	0	-190,750,000
Common Stock Issued/Repurchased	8,247,000	1,455,000	70,634,000	2,614,000
Dividends Paid	0	0	0	-3,744,000
Financing Cash Flow	-273,705,000	-186,974,000	69,600,000	54,326,000
Summary
Free Cash Flow	-138,513,000	-20,440,000	-175,170,000	-243,163,000
Net Change in Cash	-37,131,000	22,907,000	39,344,000	-353,648,000

Cash flow annual history for Coherus Oncology Inc (CHRS).
Cash Flow Statement (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Operating Activities
Net Income	168,024,000	28,507,000	-237,892,000	-291,754,000	-287,100,000
Depreciation & Amortization	0	5,276,000	3,791,000	3,699,000	3,454,000
Stock Based Compensation	0	27,802,000	43,110,000	50,737,000	51,364,000
Change in Working Capital	-5,842,000	55,894,000	-36,826,000	-79,257,000	42,360,000
Operating Cash Flow	-138,513,000	-20,440,000	-174,884,000	-241,124,000	-37,432,000
Investing Activities
Capital Expenditure	0	0	-286,000	-2,039,000	-1,289,000
Investments	0	0	-286,000	-2,039,000	-1,289,000
Investing Cash Flow	375,087,000	230,321,000	144,640,000	-166,850,000	-138,410,000
Financing Activities
Debt Repayment	-233,185,000	-223,408,000	0	-190,750,000	-672,000
Common Stock Issued/Repurchased	8,247,000	1,455,000	70,634,000	2,614,000	40,903,000
Dividends Paid	0	0	0	-3,744,000	0
Financing Cash Flow	-273,705,000	-186,974,000	69,600,000	54,326,000	51,879,000
Summary
Free Cash Flow	-138,513,000	-20,440,000	-175,170,000	-243,163,000	-38,721,000
Net Change in Cash	-37,131,000	22,907,000	39,344,000	-353,648,000	-123,963,000